复方斑蝥胶囊联合吉非替尼治疗非小细胞肺癌的临床研究

目的探讨复方斑蝥胶囊联合吉非替尼治疗非小细胞肺癌(NSCLC)的临床疗效。方法选取2015年7月—2017年7月在内蒙古自治区人民医院接受治疗的非小细胞肺癌患者80例,随机分为对照组和治疗组,每组各40例。对照组患者口服吉非替尼片治疗,0.25 g/d;治疗组患者在对照组的基础上口服复方斑蝥胶囊,3粒/次,2次/d。两组患者连续治疗9周。评价两组临床疗效,同时比较治疗前后两组患者免疫功能、血清可溶性白细胞介素-2受体(SIL-2R)、肿瘤特异性生长因子(TSGF)、血管内皮生长因子(VEGF)水平变化情况。结果治疗后,对照组临床有效率和疾病控制率分别为20.00%、60.00%,均明显低于治疗组的30.00%、82.50%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者Ig A、Ig G、Ig M表达水平均低于治疗前(P0.05),且治疗后治疗组者Ig A和Ig G水平低于对照组(P0.05)。治疗后,两组患者血清SIL-2R、TSGF表达水平明显下降(P0.05),VEGF表达水平明显升高(P0.05);且治疗后治疗组患者血清SIL-2R、TSGF和VEGF水平明显好于对照组(P0.05)。结论复方斑蝥胶囊配合吉非替尼治疗可明显提高对NSCLC的控制率,且安全性高,具有一定的临床推广应用价值。

Clinical study on Compound Banmao Capsules combined with gefitinib in treatment of non-small cell lung cancer

Objective To investigate effect of Compound Banmao Capsules combined with gefitinib in treatment of non-small cell lung cancer. Methods Patients (142 cases) with non-small cell lung cancer in the Inner Mongolia Autonomous Region People''s Hospital from July 2015 to July 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were po administered with Gefitinib Tablets, 0.25 g/d. Patients in the treatment group were po administered with Compound Banmao Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 9 weeks. After treatment, the clinical efficacy was evaluated, and the immune function, SIL-2R, TSGF and VEGF levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy and disease control rate in the control group were 20.00% and 60.00%, which were significantly lower than 30.00% and 82.50% in the treatment group, respectively, and there were differences between two groups (P < 0.05). After treatment, the IgA, IgG and IgM levels in two groups were significantly decreased (P < 0.05), and the IgA, IgG levels in the treatment group after treatment were significantly lower than that in the control group (P < 0.05). After treatment, the SIL-2R and TSGF levels in two groups were significantly decreased (P < 0.05), the VEGF levels were significantly increased (P < 0.05). And the serum SIL-2R, TSGF and VEGF levels in the treatment group after treatment were significantly better than those in the control group (P < 0.05). Conclusion Compound Banmao Capsules combined with gefitinib can significantly improve the control rate of NSCLC in treatment of non-small cell lung cancer with high safety, which has a certain clinical application value.